Hsbc Holdings PLC Has $640,000 Holdings in Silence Therapeutics PLC Sponsored ADR $SLN

Hsbc Holdings PLC decreased its holdings in Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) by 28.9% during the 1st quarter, HoldingsChannel.com reports. The firm owned 122,834 shares of the company’s stock after selling 50,000 shares during the period. Hsbc Holdings PLC’s holdings in Silence Therapeutics were worth $640,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of SLN. Boothbay Fund Management LLC increased its holdings in Silence Therapeutics by 1.0% in the second quarter. Boothbay Fund Management LLC now owns 252,421 shares of the company’s stock valued at $1,464,000 after purchasing an additional 2,409 shares during the period. Massar Capital Management LP acquired a new position in Silence Therapeutics during the 2nd quarter worth about $115,000. UBS Group AG grew its position in shares of Silence Therapeutics by 34.5% in the 3rd quarter. UBS Group AG now owns 307,363 shares of the company’s stock valued at $1,595,000 after buying an additional 78,854 shares during the last quarter. Two Sigma Investments LP grew its position in shares of Silence Therapeutics by 6.6% in the 3rd quarter. Two Sigma Investments LP now owns 63,247 shares of the company’s stock valued at $328,000 after buying an additional 3,935 shares during the last quarter. Finally, Citadel Advisors LLC acquired a new stake in shares of Silence Therapeutics in the third quarter valued at about $112,000. 98.73% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

SLN has been the subject of a number of analyst reports. Cantor Fitzgerald assumed coverage on Silence Therapeutics in a research report on Wednesday, June 24th. They set an “overweight” rating for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Silence Therapeutics in a report on Friday, July 17th. Finally, HC Wainwright reissued a “buy” rating and set a $75.00 target price on shares of Silence Therapeutics in a research report on Wednesday, June 17th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $55.00.

Silence Therapeutics Stock Up 0.6%

SLN stock opened at $11.62 on Friday. The firm has a market cap of $548.93 million, a price-to-earnings ratio of -7.31 and a beta of 1.38. Silence Therapeutics PLC Sponsored ADR has a 12-month low of $4.19 and a 12-month high of $12.19. The company’s fifty day simple moving average is $8.76 and its 200 day simple moving average is $6.94.

Silence Therapeutics (NASDAQ:SLN) last issued its quarterly earnings results on Friday, May 8th. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.14). Silence Therapeutics had a negative return on equity of 105.34% and a negative net margin of 8,943.86%.The business had revenue of $0.42 million for the quarter, compared to analyst estimates of $1.25 million. Research analysts expect that Silence Therapeutics PLC Sponsored ADR will post -1.08 earnings per share for the current year.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.